SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Take-private speculation is driving attention after reports that Papa Johns largest U.S. franchisee joined Irth Capitals bid. Traders are hopeful a sale could follow, while others remain skeptical given the boards prior rejections and the lack of a confirmed agreement.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus clinical pipeline, especially the FDA-cleared expansion of its recurrent glioblastoma REGAIN trial and anticipated data, alongside completion of the expanded pancreatic IMPACT study. Bulls view the milestones and reported demand from trial sites as encouraging, while some note that the evidence remains early and the stock has been consolidating.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Brazils presidential runoff is driving an election trade in Petrobras, with traders betting a Flvio Bolsonaro victory could bring more shareholder-friendly policies and lift the state-controlled oil company. Bulls anticipate a rally, while others caution that the outcome is uncertain and that a rally could reverse on the result; elevated oil prices also support sentiment.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is drawing attention around the launch of Keeta Personal and its ACH-enabled banking and payment features, which traders connect to Visa Direct, Bivo Cash and broader tokenized-fiat plans. Bulls see the partnerships and product rollout as potential adoption drivers, while skeptics say they have yet to produce sustained network activity or price gains.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

LLY is drawing attention around its upcoming quarterly report, with traders debating whether demand for Mounjaro and Zepboundand growth from oral obesity drug Foundayocan sustain momentum and support higher guidance. Optimism about a potential earnings beat and recent highs is tempered by concerns about valuation, competition and drug tolerability.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Golds sharp pullback is the main focus, with traders linking pressure to a stronger U.S. dollar, rising Treasury yields and hawkish Fed rate expectations. The community is split between buying the dip and expecting further weakness, with some watching for signs that gold has found support.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans quarterly results, higher full-year guidance, and record backlog are drawing attention, with traders pointing to strong defense demand and long-term revenue visibility. The reaction is broadly constructive, though some question whether margin pressure and the stocks recent weakness temper the bullish outlook.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs selloff after earnings is driving discussion, with traders questioning why the shares fell despite improvements in profitability and cash flow. The debate centers on whether the companys cash, buybacks, and low valuation can offset concerns about declining revenue, weak Chinese consumer demand, and broader pressure on China stocks.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMCs sharply reduced outlook, driven by weak demand and major pricing adjustments to clear distributor inventory, has intensified concern about its debt and financial stability. Traders are divided between fears of further restructuring or bankruptcy and a turnaround case built on debt reduction and an eventual recovery as inventories normalize.

Cash Cat

A volatile rally to record highs has driven attention, with bulls connecting CASHCATs momentum to its Robinhood-chain role and anticipated ecosystem activity, while skeptics point to sharp reversals and question the tokens utility. Claims about short squeezes, manipulation, and buybacks remain community speculation rather than confirmed catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.read more...

Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know

Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Atea Pharmaceuticals (AVIR) This Year?

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround 

Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Tuesday

Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-atea-pharmaceuticals-inc-stock...

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 1.6% - Still a Buy?

Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 1.6% - Time to Buy...

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 5.9% - Here's Why

Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 5.9% - Time to Buy...

Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why

Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year High - What's Next...

Atea Pharmaceuticals Q4 Earnings Call Highlights

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its...

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Atea Pharmaceuticals Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$4.04
Prev Close	$4.05
Open	$4.03
Dividend Yield	0.00%
50-Day Moving Average	$5.15
Beta	0.78
Avg. Volume	297,027.33
PE Ratio	-1.93

52-Week High	$6.45
52-Week Low	$2.87
Market Capitalization	$324.03M
EPS (Annual)	-$1.94
Price to Book	1.59
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AVIR Fundamentals